Andreas A Argyriou1, Konstantinos Assimakopoulos2, Gregoris Iconomou3, Fotini Giannakopoulou3, Haralabos P Kalofonos3. 1. Department of Neurology, Saint Andrew's General Hospital of Patras, Patras, Greece; Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Rion-Patras, Greece. 2. Department of Psychiatry, University of Patras Medical School, Rion-Patras, Greece. 3. Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Rion-Patras, Greece.
Abstract
CONTEXT: In recent years, there is growing evidence in the medical literature to support an association between administration of commonly used chemotherapeutic agents and an increased risk for cognitive impairment. OBJECTIVES: We herein critically summarize data relating to the pathophysiological mechanisms by which chemotherapy may induce cognitive impairment in patients surviving from solid tumors. The clinical and epidemiological characteristics and the proposed management strategies to counter chemotherapy-induced cognitive impairment (CICI) also are presented. METHODS: References for this review were identified by searches of PubMed from 1995 until December 2009 with related terms. RESULTS: Both the pathogenetic mechanisms and the overall clinical nature of CICI remain vaguely defined. Findings indicate that CICI is a relatively common event that, in most of the cases, remains underdiagnosed, thereby adversely affecting the quality of life of patients with cancer. Effective pharmacological interventions toward the symptomatic or prophylactic management of CICI also are lacking. CONCLUSION: Either called "chemobrain" or "chemofog," the long-term CICI in cancer survivors is real. The need for multidisciplinary care interventions toward a timely diagnosis and management of CICI is clearly warranted.
CONTEXT: In recent years, there is growing evidence in the medical literature to support an association between administration of commonly used chemotherapeutic agents and an increased risk for cognitive impairment. OBJECTIVES: We herein critically summarize data relating to the pathophysiological mechanisms by which chemotherapy may induce cognitive impairment in patients surviving from solid tumors. The clinical and epidemiological characteristics and the proposed management strategies to counter chemotherapy-induced cognitive impairment (CICI) also are presented. METHODS: References for this review were identified by searches of PubMed from 1995 until December 2009 with related terms. RESULTS: Both the pathogenetic mechanisms and the overall clinical nature of CICI remain vaguely defined. Findings indicate that CICI is a relatively common event that, in most of the cases, remains underdiagnosed, thereby adversely affecting the quality of life of patients with cancer. Effective pharmacological interventions toward the symptomatic or prophylactic management of CICI also are lacking. CONCLUSION: Either called "chemobrain" or "chemofog," the long-term CICI in cancer survivors is real. The need for multidisciplinary care interventions toward a timely diagnosis and management of CICI is clearly warranted.
Authors: Sara Jane Ward; Sean D McAllister; Rumi Kawamura; Ryuchi Murase; Harshini Neelakantan; Ellen A Walker Journal: Br J Pharmacol Date: 2014-02 Impact factor: 8.739
Authors: Daniel P Fitzgerald; Preeti Subramanian; Monika Deshpande; Christian Graves; Ira Gordon; Yongzhen Qian; Yeva Snitkovsky; David J Liewehr; Seth M Steinberg; José D Paltán-Ortiz; Mary M Herman; Kevin Camphausen; Diane Palmieri; S Patricia Becerra; Patricia S Steeg Journal: Cancer Res Date: 2012-01-01 Impact factor: 12.701
Authors: Giovanni G Arcuri; Lisa Palladini; Gabrielle Dumas; Josée Lemoignan; Bruno Gagnon Journal: Support Care Cancer Date: 2015-02-14 Impact factor: 3.603
Authors: K L Pomykala; P A Ganz; J E Bower; L Kwan; S A Castellon; S Mallam; I Cheng; R Ahn; E C Breen; M R Irwin; D H S Silverman Journal: Brain Imaging Behav Date: 2013-12 Impact factor: 3.978